Early-Stage healthcare and life science investment firm

Zogenix (NASDAQ: ZGNX) is committed to developing and commercializing therapies for central nervous system disorders that address specific clinical needs for people living with orphan diseases and other CNS disorders who need innovative treatment alternatives to improve their daily functioning

Pwervision is developing the FluidVision® accommodating intraocular lens (IOL). This technology will restore the vision of youth to middle aged or elderly individuals affected by presbyopia and/or cataracts. The Company's mission is to provide a family of fluid based lens implants that solve clinical and lifestyle needs caused by these conditions thereby creating the most significant innovation in vision correction surgery since the introduction of the IOL.

SkySong Innovations is the exclusive intellectual property management and technology transfer organization for Arizona State University (ASU). We work with faculty, investors and our industry partners to translate ASU innovation into broad societal impact.

Orexigen Therapeutics, Inc. was a biopharmaceutical company focused on the treatment of obesity. Orexigen’s first medicine, Contrave® (naltrexone HCl and bupropion HCl extended release), was approved in the United States in September 2014. In Europe the drug has been approved under the brand name Mysimba® (naltrexone HCl/ bupropion HCl prolonged release).

Molecular Templates is a biotechnology company focused on the discovery, development, and commercialization of a next-generation of immunotoxins for the treatment of cancers and other serious disease

Cardiokinetix, based in Menlo Park, CA, has developed a novel transcatheter implant called the Parachute® Ventricular Partitioning Device (Parachute). The Parachute intends to treat heart failure resulting from a heart attack in patients worldwide by improving overall cardiac function.

Heat Biologics (NASDAQ: HTBX) is a clinical-stage company focused on developing its proprietary “ImPACT” (Immune Pan-Antigen Cytotoxic Therapy) fully allogeneic cell based immunotherapy for use in the treatment of a wide range of cancers and infectious diseases.

Hospice is a program of care and support for a person diagnosed with a terminal illness and comfort care is desired. Helping people find meaning and peace is at the core of our mission.At New Century Hospice, our program supports early involvement where a dramatic difference in the quality of life can be experienced. By enabling families and loved ones to participate in the care experience, we are able to make the remaining time more meaningful, dignified and comfortable.

Scale Venture Partners is a venture capital firm that invests primarily in early-in-revenue technology companies with a focus on Internet, cloud computing, software as a service, and mobile products. The firm is based in Foster City, Californiahttps://www.scalevp.com

Horizon Pharma plc (NASDAQ: HZNP) is a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets nine medicines through its orphan, primary care and rheumatology business units. Horizon’s global headquarters are in Dublin, Ireland.

Seattle Genetics (NASDAQ: SGEN) is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. ADCs are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing anti-tumor activity.

Gilead Sciences (NASDAQ: GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer and inflammation, and serious respiratory and cardiovascular conditions.The Company's portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.